These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36758543)

  • 1. ATP-competitive and allosteric inhibitors induce differential conformational changes at the autoinhibitory interface of Akt1.
    Shaw AL; Parson MAH; Truebestein L; Jenkins ML; Leonard TA; Burke JE
    Structure; 2023 Mar; 31(3):343-354.e3. PubMed ID: 36758543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsecond molecular dynamics simulations provide insight into the ATP-competitive inhibitor-induced allosteric protection of Akt kinase phosphorylation.
    Mou L; Cui T; Liu W; Zhang H; Cai Z; Lu S; Gao G
    Chem Biol Drug Des; 2017 May; 89(5):723-731. PubMed ID: 27797456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.
    Parikh C; Janakiraman V; Wu WI; Foo CK; Kljavin NM; Chaudhuri S; Stawiski E; Lee B; Lin J; Li H; Lorenzo MN; Yuan W; Guillory J; Jackson M; Rondon J; Franke Y; Bowman KK; Sagolla M; Stinson J; Wu TD; Wu J; Stokoe D; Stern HM; Brandhuber BJ; Lin K; Skelton NJ; Seshagiri S
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19368-73. PubMed ID: 23134728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An ATP-site on-off switch that restricts phosphatase accessibility of Akt.
    Lin K; Lin J; Wu WI; Ballard J; Lee BB; Gloor SL; Vigers GP; Morales TH; Friedman LS; Skelton N; Brandhuber BJ
    Sci Signal; 2012 May; 5(223):ra37. PubMed ID: 22569334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
    Lindsley CW; Barnett SF; Layton ME; Bilodeau MT
    Curr Cancer Drug Targets; 2008 Feb; 8(1):7-18. PubMed ID: 18288939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises.
    Pervanidis KA; D'Angelo GD; Weisner J; Brandherm S; Rauh D
    J Med Chem; 2024 Apr; 67(8):6052-6063. PubMed ID: 38592948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition.
    Wu WI; Voegtli WC; Sturgis HL; Dizon FP; Vigers GP; Brandhuber BJ
    PLoS One; 2010 Sep; 5(9):e12913. PubMed ID: 20886116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
    Lindsley CW; Barnett SF; Yaroschak M; Bilodeau MT; Layton ME
    Curr Top Med Chem; 2007; 7(14):1349-63. PubMed ID: 17692025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
    Politz O; Siegel F; Bärfacker L; Bömer U; Hägebarth A; Scott WJ; Michels M; Ince S; Neuhaus R; Meyer K; Fernández-Montalván AE; Liu N; von Nussbaum F; Mumberg D; Ziegelbauer K
    Int J Cancer; 2017 Jan; 140(2):449-459. PubMed ID: 27699769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity.
    Kostaras E; Kaserer T; Lazaro G; Heuss SF; Hussain A; Casado P; Hayes A; Yandim C; Palaskas N; Yu Y; Schwartz B; Raynaud F; Chung YL; Cutillas PR; Vivanco I
    Br J Cancer; 2020 Aug; 123(4):542-555. PubMed ID: 32439931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination.
    Jo H; Lo PK; Li Y; Loison F; Green S; Wang J; Silberstein LE; Ye K; Chen H; Luo HR
    Proc Natl Acad Sci U S A; 2011 Apr; 108(16):6486-91. PubMed ID: 21464312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developments in selective small molecule ATP-targeting the serine/threonine kinase Akt/PKB.
    Wang P; Zhang L; Hao Q; Zhao G
    Mini Rev Med Chem; 2011 Nov; 11(13):1093-107. PubMed ID: 22353219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of inter-domain stabilizers-a novel assay system for allosteric akt inhibitors.
    Fang Z; Simard JR; Plenker D; Nguyen HD; Phan T; Wolle P; Baumeister S; Rauh D
    ACS Chem Biol; 2015 Jan; 10(1):279-88. PubMed ID: 24959717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent-Allosteric Kinase Inhibitors.
    Weisner J; Gontla R; van der Westhuizen L; Oeck S; Ketzer J; Janning P; Richters A; Mühlenberg T; Fang Z; Taher A; Jendrossek V; Pelly SC; Bauer S; van Otterlo WA; Rauh D
    Angew Chem Int Ed Engl; 2015 Aug; 54(35):10313-6. PubMed ID: 26110718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into the structural mechanism for PKBα allosteric inhibition by molecular dynamics simulations and free energy calculations.
    Chen SF; Cao Y; Han S; Chen JZ
    J Mol Graph Model; 2014 Mar; 48():36-46. PubMed ID: 24374242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational changes in Akt1 activation probed by amide hydrogen/deuterium exchange and nano-electrospray ionization mass spectrometry.
    Guo M; Huang BX; Kim HY
    Rapid Commun Mass Spectrom; 2009 Jul; 23(13):1885-91. PubMed ID: 19462409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Mechanism of ATP-Dependent Allosteric Protection of Akt Kinase Phosphorylation.
    Lu S; Deng R; Jiang H; Song H; Li S; Shen Q; Huang W; Nussinov R; Yu J; Zhang J
    Structure; 2015 Sep; 23(9):1725-1734. PubMed ID: 26256536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Akt1 allosteric site to identify novel scaffolds through virtual screening.
    Yilmaz OG; Olmez EO; Ulgen KO
    Comput Biol Chem; 2014 Feb; 48():1-13. PubMed ID: 24291487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FCX-146, a potent allosteric inhibitor of Akt kinase in cancer cells: Lead optimization of the second-generation arylidene indanone scaffold.
    Balasubramaniam M; Lakkaniga NR; Dera AA; Fayi MA; Abohashrh M; Ahmad I; Chandramoorthy HC; Nalini G; Rajagopalan P
    Biotechnol Appl Biochem; 2021 Feb; 68(1):82-91. PubMed ID: 32067263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors in AKTion: ATP-competitive vs allosteric.
    Lazaro G; Kostaras E; Vivanco I
    Biochem Soc Trans; 2020 Jun; 48(3):933-943. PubMed ID: 32453400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.